Beijing Wantai Biological Pharmacy Enterprise Balance Sheet Health
Financial Health criteria checks 5/6
Beijing Wantai Biological Pharmacy Enterprise has a total shareholder equity of CN¥12.6B and total debt of CN¥267.0M, which brings its debt-to-equity ratio to 2.1%. Its total assets and total liabilities are CN¥14.7B and CN¥2.1B respectively.
Key information
2.1%
Debt to equity ratio
CN¥267.03m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥5.50b |
| Equity | CN¥12.61b |
| Total liabilities | CN¥2.13b |
| Total assets | CN¥14.74b |
Recent financial health updates
Recent updates
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year
Jul 26
These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well
Jul 22Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Financial Position Analysis
Short Term Liabilities: 603392's short term assets (CN¥9.0B) exceed its short term liabilities (CN¥1.9B).
Long Term Liabilities: 603392's short term assets (CN¥9.0B) exceed its long term liabilities (CN¥180.9M).
Debt to Equity History and Analysis
Debt Level: 603392 has more cash than its total debt.
Reducing Debt: 603392 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: 603392's debt is well covered by operating cash flow (316.3%).
Interest Coverage: Insufficient data to determine if 603392's interest payments on its debt are well covered by EBIT.